Background Patients with advanced hepatocellular carcinoma and increased α-fetoprotein
concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in …

Advancement in systemic therapy, particularly immune checkpoint inhibitor (ICI)-based
combination regimens, has transformed the treatment landscape for patients with advanced …

Abstract Purpose: The phase III CELESTIAL study demonstrated improved overall survival
(OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with …

Background: Our previous study has demonstrated an oncogenic role of PIWI-interacting
RNA-54265 (piR-54265) in colorectal cancer (CRC). Here, we investigate whether it can be …

Over the past ten years, sorafenib, a multikinase inhibitor, has been the standard of care for
patients with unresectable hepatocellular carcinoma (HCC) and well-preserved liver …

AIM To investigate whether the change in pre-/post-operation serum alpha-fetoprotein (AFP)
levels is a predictive factor for hepatocellular carcinoma (HCC) outcomes. METHODS We …

Simple Summary The prognosis of hepatocellular carcinoma is mainly driven by the stage of
the tumor and by the overall liver function status. However, survival rates of patients with …

Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly
improved overall survival (OS) and progression-free survival (PFS) versus placebo in …

Introduction Hepatocellular carcinoma (HCC) is the most common primary liver cancer with
a low 5-year survival rate. The heterogeneity of HCC makes monotherapy unlikely. The …

A large cohort of hepatocellular carcinoma (HCC) patients from several collaborating
Turkish institutions were examined for the tumor parameters of maximum diameter (MTD) …